Zacks: Brokerages Expect Sensus Healthcare Inc (NASDAQ:SRTS) to Post -$0.03 EPS

Share on StockTwits

Equities research analysts predict that Sensus Healthcare Inc (NASDAQ:SRTS) will post earnings per share of ($0.03) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.00. Sensus Healthcare posted earnings of ($0.04) per share in the same quarter last year, which indicates a positive year over year growth rate of 25%. The business is expected to report its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Sensus Healthcare will report full year earnings of ($0.13) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.01). For the next year, analysts expect that the firm will report earnings of $0.25 per share, with EPS estimates ranging from $0.02 to $0.40. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Sensus Healthcare.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.11). Sensus Healthcare had a negative net margin of 11.65% and a negative return on equity of 13.34%. The business had revenue of $5.44 million for the quarter, compared to analysts’ expectations of $7.81 million.

Several equities analysts recently commented on the stock. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Maxim Group set a $7.00 price target on shares of Net 1 UEPS Technologies and gave the company a “buy” rating in a research report on Friday, May 10th. TheStreet cut shares of Wayside Technology Group from a “b-” rating to a “c” rating in a research report on Wednesday, May 22nd. HC Wainwright increased their price target on shares of Acceleron Pharma from $66.00 to $69.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Finally, Alliance Global Partners cut shares of Sensus Healthcare from a “buy” rating to a “neutral” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $10.00.

Shares of NASDAQ:SRTS traded up $0.04 during trading on Thursday, reaching $5.35. The company had a trading volume of 195 shares, compared to its average volume of 9,958. The company has a fifty day moving average price of $5.38. The stock has a market cap of $88.54 million, a PE ratio of -38.46 and a beta of -0.20. Sensus Healthcare has a 12 month low of $4.75 and a 12 month high of $9.23.

Large investors have recently bought and sold shares of the company. Garrison Bradford & Associates Inc. increased its stake in Sensus Healthcare by 275.1% during the 1st quarter. Garrison Bradford & Associates Inc. now owns 108,400 shares of the company’s stock valued at $761,000 after purchasing an additional 79,500 shares in the last quarter. B. Riley Wealth Management Inc. bought a new stake in Sensus Healthcare during the 1st quarter valued at about $117,000. Northern Trust Corp bought a new stake in Sensus Healthcare during the 4th quarter valued at about $86,000. Spark Investment Management LLC bought a new stake in Sensus Healthcare during the 1st quarter valued at about $155,000. Finally, B. Riley Financial Inc. bought a new stake in Sensus Healthcare during the 1st quarter valued at about $281,000. 9.56% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Recommended Story: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Sensus Healthcare (SRTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Avaya  Earns “Buy” Rating from Northland Securities
Avaya Earns “Buy” Rating from Northland Securities
Bloom Energy  Earns Overweight Rating from KeyCorp
Bloom Energy Earns Overweight Rating from KeyCorp
Bristol-Myers Squibb  Lifted to “Overweight” at Atlantic Securities
Bristol-Myers Squibb Lifted to “Overweight” at Atlantic Securities
Argus Boosts AstraZeneca  Price Target to $50.00
Argus Boosts AstraZeneca Price Target to $50.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines  Price Target to $83.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines Price Target to $83.00
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust


© 2006-2019 Ticker Report